| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
|
SPDB-DM4 is a novel drug-linker conjugate used for the synthesis of antibody-drug-conjugate (ADC) with maytansine as the payload (DM4) which is connected to the antibody part via a SPDB linker, exhibiting potent anti-tumor activity.
| Targets |
Maytansinoids
|
|---|---|
| References |
| Molecular Formula |
H5MBPS
|
|---|---|
| Molecular Weight |
78.8895
|
| Exact Mass |
994.347
|
| CAS # |
1626359-62-3
|
| PubChem CID |
162393097
|
| Appearance |
White to light yellow solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
67
|
| Complexity |
1910
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@]1([C@H](CC(N(C(C=C2C=C3OC)=C3Cl)C)=O)OC([C@H](C)N(C)C(CCC(C)(C)SSCCCC(ON(C4=O)C(CC4)=O)=O)=O)=O)[C@H]([C@@H]([C@](OC5=O)([H])C[C@]([C@](/C=C/C=C(C)/C2)([H])OC)(N5)O)C)O1
|
| InChi Key |
LAVNQRWLLQGEIB-UHAQQUCISA-N
|
| InChi Code |
InChI=1S/C46H63ClN4O14S2/c1-26-13-11-14-33(61-10)46(59)25-32(62-43(58)48-46)27(2)41-45(6,64-41)34(24-38(55)50(8)30-22-29(21-26)23-31(60-9)40(30)47)63-42(57)28(3)49(7)35(52)18-19-44(4,5)67-66-20-12-15-39(56)65-51-36(53)16-17-37(51)54/h11,13-14,22-23,27-28,32-34,41,59H,12,15-21,24-25H2,1-10H3,(H,48,58)/t27-,28+,32+,33-,34?,41+,45+,46+/m1/s1
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]butanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 300 mg/mL (~301.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.51 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+ 40% PEG300+ 5% Tween-80+ 45% saline: ≥ 2.5 mg/mL (2.51 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 12.6759 mL | 63.3794 mL | 126.7588 mL | |
| 5 mM | 2.5352 mL | 12.6759 mL | 25.3518 mL | |
| 10 mM | 1.2676 mL | 6.3379 mL | 12.6759 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03106077 | Completed | Biological: Mirvetuximab Soravtansine |
Anatomic Stage II Breast Cancer AJCC v8 | M.D. Anderson Cancer Center | June 5, 2017 | Phase 2 |
| NCT03552471 | Active, not recruiting | Other: Laboratory Biomarker Analysis Biological: Mirvetuximab Soravtansine |
BRCA1 Gene Mutation | Ohio State University Comprehensive Cancer Center | July 12, 2018 | Phase 1 |
| NCT02996825 | Active, not recruiting | Drug: Gemcitabine Drug: Gemcitabine Hydrochloride |
Recurrent Breast Carcinoma | City of Hope Medical Center | March 22, 2017 | Phase 1 |
| NCT00674947 | Completed | Drug: BIIB015 | Solid Tumors | Biogen | June 2008 | Phase 1 |
| NCT05703555 | Not yet recruiting | ravtansine | Metastatic Lung Cancer | Erasmus Medical Center | February 2023 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
